Bavarian Nordic A/S (ETR:BV3)

Market Cap	2.38B -1.2%
Revenue (ttm)	847.76M -1.8%
Net Income	206.34M +8.4%
EPS	2.60 +8.1%
Shares Out	n/a
PE Ratio	10.95
Forward PE	18.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222
Open	31.32
Previous Close	29.54
Day's Range	31.06 - 31.32
52-Week Range	22.96 - 32.69
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,906
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BV3

Financial Performance

In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 8, 2026

Data Sources Report a data error